Bharat Parenterals
BPLPHARMABSE

Bharat Parenterals

₹1,325.850.00 (0.00%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,320.00
Today’s high
1,390.00
52 week low
880.25
52 week high
1,667.20
Open price
1,388.35
Previous close
1,325.85
Live volume
--
Lower circuit
1,060.70
Upper circuit
1,591.00

Fundamentals

Market Cap
₹914Cr
ROE
-2.54%
P/E Ratio(TTM)
-28.59
EPS(TTM)
-39.62
P/B Ratio
2.84
Dividend Yield
0.08%
Industry P/E
33.73
Book Value
467.55
Debt to Equity
0.45
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹103
+55.22%
Profit (Cr)
-₹8.16
+15.62%
-50050100150
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)-3%
3Y CAGR+17%
Profit growthValue
1Y (TTM)+16%

About

Bharat Parenterals Limited is a public company based in India, specializing in the manufacturing of diverse pharmaceutical formulations for a global customer base. The company envisions becoming a leading manufacturer of formulations by harnessing its strong resource base to meet industry challenges and seize growth opportunities ahead. Through its Corporate Social Responsibility policy, the company encourages a strong commitment from the organization and employees to address the healthcare challenges of the country. Its core business is centered on the manufacturing and marketing of drug formulations, supported by research and development to ensure cost-competitiveness and regulatory compliance. The company's strategy involves the continual expansion of its product lines and customer base by systematically reinforcing its quality, innovation, and cost-efficiency. With a WHO-cGMP certified modern production facility and over 500 formulations, the company conforms to international standards and has established a global export footprint.;
CEO/MD
Mr. Bharat R. Desai
Founded in
1992
BSE symbol
541096

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
67.17%
Retail And Others
31.66%
Other Domestic Institutions
1.06%
Foreign Institutions
0.11%
Livesquawk
Bharat Parenterals reported a Q4 net loss of ₹48M, up from ₹47M YoY. Q4 revenue declined to ₹996M from ₹1B YoY, reflecting a slight drop.
Livesquawk
Bharat Parenterals: U.S. FDA inspected InnoXel Lifesciences, issued 5 VAI observations. Final Establishment Inspection Report (EIR) from FDA is awaited.
Livesquawk
Bharat Parenter reported Q3 net loss of ₹44M vs ₹16.6M YoY. Q3 revenue declined to ₹652M from ₹722M YoY.
2026
18
May
Quarterly & Annual Result
Release date
30
Jan
Quarterly Result
Release date
2025
12
Nov
Quarterly Result
Release date

19
Sep
Dividend
Ex date
₹1.00
per share

For each share you hold, you will receive ₹1.00
Dividend amount₹1.00 per share
Dividend TypeFinal
Ex Date19 Sep ‘25
Record Date19 Sep ‘25
Announcement date12 May ‘25
28
Jul
Quarterly Result
Release date

12
May
Dividend
Announced
₹1.00
per share

For each share you hold, you will receive ₹1.00
Dividend amount₹1.00 per share
Dividend TypeFinal
Ex Date19 Sep ‘25
Record Date19 Sep ‘25
Announcement date12 May ‘25
2024

25
Jun
Dividend
Ex date
₹1.00
per share

For each share you hold, you will receive ₹1.00
Dividend amount₹1.00 per share
Dividend TypeFinal
Ex Date25 Jun ‘24
Record Date25 Jun ‘24
Announcement date22 May ‘24
Events calendar
View upcoming events in other stocks